Foamix Pharmaceuticals has commenced patient dosing in a Phase III clinical trial (FX2017-22) of its product candidate FMX101 in patients with moderate-to-severe acne.

FMX101 is a topical drug candidate with 4% minocycline foam being developed for the treatment of acne.

The double-blind, vehicle-controlled, multi-centre Phase III trial will evaluate once-daily FMX101 in 1,500 patients over 12 weeks at approximately 80 clinical centres across the US.

Foamix Pharmaceuticals CEO David Domzalski said: "During a recent type B meeting, the US Food and Drug Administration (FDA) confirmed that statistically significant findings from a third study would constitute replication of the study FX2014-05 results, and would be sufficient to establish an efficacy claim.

“This confirmation supports our plans for conducting a third Phase III study.”

"This confirmation supports our plans for conducting a third Phase III study."

The primary endpoints of the trial are the proportion of patients reporting success at week 12 as indicated by an investigator's global assessment and mean change in inflammatory lesion counts from baseline at week 12.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Additionally, the trial will assess the safety of the product candidate through reported adverse events, tolerability, clinical laboratory tests and vital signs.

Top-line results from the Phase III trial are expected to be available by mid next year.

Foamix is also planning to conduct a parallel, long-term, open-label safety extension study to investigate the safety of intermittent use of FMX101. The extension study is estimated to be completed by the end of this year.